Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

David Planchard; Benjamin Besse; Harry Groen; Sayed Hashemi; Julien Mazieres; Tae Min Kim; Elisabeth A. Quoix; Pierre Jean Souquet; Fabrice Barlesi; Christina S. Baik; Liza C. Villaruz; Ronan Joseph Kelly; Shirong Zhang; Monique Tan; Eduard Gasal; Libero Santarpia; Bruce E. Johnson

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

David Planchard, Benjamin Besse, Harry Groen, Sayed Hashemi, Julien Mazieres, Tae Min Kim, Elisabeth A. Quoix, Pierre Jean Souquet, Fabrice Barlesi, Christina S. Baik, Liza C. Villaruz, Ronan Joseph Kelly, Shirong Zhang, Monique Tan, Eduard Gasal, Libero Santarpia, Bruce E. Johnson

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Journal of clinical oncology
Volume	38
Issue number	15
Publication status	Published - 20 May 2020

Cite this

Planchard, D., Besse, B., Groen, H., Hashemi, S., Mazieres, J., Kim, T. M., Quoix, E. A., Souquet, P. J., Barlesi, F., Baik, C. S., Villaruz, L. C., Kelly, R. J., Zhang, S., Tan, M., Gasal, E., Santarpia, L., & Johnson, B. E. (2020). Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). Journal of clinical oncology, 38(15).

@article{145a1e708d2241d7b2b26df39d0a933f,

title = "Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).",

author = "David Planchard and Benjamin Besse and Harry Groen and Sayed Hashemi and Julien Mazieres and Kim, {Tae Min} and Quoix, {Elisabeth A.} and Souquet, {Pierre Jean} and Fabrice Barlesi and Baik, {Christina S.} and Villaruz, {Liza C.} and Kelly, {Ronan Joseph} and Shirong Zhang and Monique Tan and Eduard Gasal and Libero Santarpia and Johnson, {Bruce E.}",

year = "2020",

month = may,

day = "20",

language = "English",

volume = "38",

journal = "Journal of clinical oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Planchard, D, Besse, B, Groen, H, Hashemi, S, Mazieres, J, Kim, TM, Quoix, EA, Souquet, PJ, Barlesi, F, Baik, CS, Villaruz, LC, Kelly, RJ, Zhang, S, Tan, M, Gasal, E, Santarpia, L & Johnson, BE 2020, 'Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).', Journal of clinical oncology, vol. 38, no. 15.

Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). / Planchard, David; Besse, Benjamin; Groen, Harry et al.
In: Journal of clinical oncology, Vol. 38, No. 15, 20.05.2020.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) plus trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC).

AU - Planchard, David

AU - Besse, Benjamin

AU - Groen, Harry

AU - Hashemi, Sayed

AU - Mazieres, Julien

AU - Kim, Tae Min

AU - Quoix, Elisabeth A.

AU - Souquet, Pierre Jean

AU - Barlesi, Fabrice

AU - Baik, Christina S.

AU - Villaruz, Liza C.

AU - Kelly, Ronan Joseph

AU - Zhang, Shirong

AU - Tan, Monique

AU - Gasal, Eduard

AU - Santarpia, Libero

AU - Johnson, Bruce E.

PY - 2020/5/20

Y1 - 2020/5/20

M3 - Meeting Abstract

SN - 0732-183X

VL - 38

JO - Journal of clinical oncology

JF - Journal of clinical oncology

IS - 15

ER -